GLP-1 agonists are a drug class that mimic the glucagon-like peptide-1 (GLP-1) hormone, which regulates blood sugar and appetite. They are widely used in type 2 diabetes treatment and have shown significant cardiovascular benefits. More than 38 million Americans are diagnosed with diabetes, which demands innovative therapies. GLP-1 agonist therapeutic products, such as Semaglutide and Tirzepatide, are advancing with dual and triple agonist mechanisms. The focus on weight management and cardiometabolic health is expected to drive substantial market growth in the coming years.
Major companies involved in the GLP-1 agonists pipeline drugs market include Eli Lilly and Company, Rose Pharma Inc., Biomed Industries, Inc., and others.
Leading drugs currently in the pipeline include Tirzepatide, GZR18, and others.
Expanding indications, novel formulations, and strong clinical trial data are accelerating the GLP-1 agonists pipeline. In December 2024, the FDA approved the generic GLP-1 agonists for type 2 diabetes, boosting market competition.
The GLP-1 Agonists Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into GLP-1 agonists therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for GLP-1 agonists. The GLP-1 agonists report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The GLP-1 agonists pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with GLP-1 agonists treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to GLP-1 agonists.
GLP-1 (Glucagon-Like Peptide-1) agonists are a class of drugs that mimic the GLP-1 hormone, which regulates blood sugar and appetite. These agents stimulate insulin secretion, suppress glucagon release, and slow gastric emptying. They are primarily peptide-based and engineered for prolonged activity, improving metabolic control in patients with diabetes and obesity.
GLP-1 agonists are widely used in the treatment of type 2 diabetes mellitus (T2DM) by enhancing insulin response and reducing postprandial glucose levels. They are also approved for weight management in obesity by promoting satiety and reducing calorie intake. There is ongoing research on exploring their potential in cardiovascular diseases and neurodegenerative disorders, thereby, expanding their therapeutic applications beyond diabetes.
This section of the report covers the analysis of GLP-1 agonists drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total GLP-1 agonists clinical trials.
The drug molecule categories covered under the GLP-1 agonists pipeline analysis include peptides, small molecules, mRNA-based therapies, and antibody-based therapies. The GLP-1 agonists report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for GLP-1 agonists. Some of the approved GLP-1 agonists are Dulaglutide (Trulicity®), Exenatide (Byetta®), Exenatide extended-release (Bydureon®), Liraglutide (Victoza®), Lixisenatide (Adlyxin®) and Semaglutide injection (Ozempic®).
The EMR report for the GLP-1 agonists drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed GLP-1 agonists therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in GLP-1 agonists clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for GLP-1 agonists. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of GLP-1 agonists drug candidates.
Tirzepatide, sponsored by Eli Lilly and Company, is a dual GIP/GLP-1 receptor agonist designed to regulate metabolism through peripheral organs and the central nervous system. The ongoing Phase III SURPASS-CVOT trial is evaluating the efficacy and safety of Tirzepatide, compared to dulaglutide in patients with Type 2 diabetes and high cardiovascular risk. This study aims to provide insights into diabetes treatment and the role of GIP in its pathogenesis.
GZR18, developed by Gan and Lee Pharmaceuticals, USA, is currently undergoing a Phase II trial to assess its efficacy and safety for weight management in obese or overweight individuals. GZR18, a novel GLP-1 analog, has demonstrated promising pharmacokinetics, glucose-lowering effects, and weight reduction potential in preclinical models. This study is evaluating 24, 36, and 48 mg doses of GZR18 (Q2W) against placebo and 15 mg tirzepatide (QW).
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The GLP-1 Agonists Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for GLP-1 agonists. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into GLP-1 agonists collaborations, regulatory environments, and potential growth opportunities.
Obesity Market Report and Forecast
Global Diabetes Drugs Market Report and Forecast
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share